A cerebrospinal fluid (CSF) shunt system is used for treatment of hydrocephalus and abnormal intracranial pressure (ICP) conditions. Mostly a shunt system is placed under skin for creating a low resistance pathway between intracranial space and appropriate discharge sites within body by doing so excess CSF volume can exit the intracranial space. Displaced intracranial CSF volume normally results in lowered ICP. Thereby, a CSF shunt can manage ICP. In a healthy person, normal ICP is primarily maintained by CSF production and reabsorption rate as a natural tendency of body. If intracranial CSF volume starts increasing due to under reabsorption, this mostly results in raised ICP. Abnormal ICP can be treated by discharging excess CSF volume via use of a shunt system. Once a shunt system is placed subcutaneously, a patient is expected to live a normal life. However, shunt failure as well as flow regulatory problems are major issues with current passive shunt systems which leaves patients with serious consequences of under-/over CSF drainage condition. In this research, a shunt system is developed which is resistant to most shunt-related causes of under-/over CSF drainage. This has been made possible via use of an on-board medical monitoring (diagnostic) and active flow control mechanism. The developed shunt system, in this research, has full external ventricular drainage (EVD) capability. Further miniaturization will make it possible for an implantable shunt. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2020. / FAU Electronic Theses and Dissertations Collection

Thesis (M.S.)--Brigham Young University. Dept. of Electrical and Computer Engineering, 2006. / Includes bibliographical references (p. 79-81).

Professional research project (Au.D.)--University of South Florida, 2000. / Title from PDF of title page. / Document formatted into pages; contains 22 pages. / Includes bibliographical references. / Text (Electronic thesis) in PDF format. / ABSTRACT: The purpose of this study was to investigate further the characteristics of hearing loss in ventriculoperitoneal (VP) shunted hydrocephalus. Twelve (VP) shunt treated hydrocephalus children participated in this study. The etiology of the hydrocephalus was either intraventricular hemorrhage or spina bifida. A recent neurological examination reported the shunt to be patent in each child. Audiometric examination included pure tone air conduction thresholds, tympanometry, contralateral and ipsilateral acoustic reflex thresholds and distortion product otoacoustic emissions (DPOAE&softsign;s). A unilateral, high frequency, sensorineural hearing loss was found in the ear ipsilateral to shunt placement in 10 (83%) of the 12 shunt treated hydrocephalic children. No hearing loss was observed the ear contralateral to shunt placement. Based on the pure tone findings coupled with the decrease in DPOAE amplitude in the shunt ear, the hearing loss appears to be cochlear in nature. It is hypothesized that the cochlear hydrodynamics are disrupted as the result of fluid pressure reduction within the perilymph being transmitted via a patent cochlear aqueduct as a reaction to the reduction of CSF via a patent shunt. In addition, a concomitant brainstem involvement is evidenced in the ART pattern possibly produced by the paten shunt draining CSF from the subdural space resulting in cranial base hypoplasia. / System requirements: World Wide Web browser and PDF reader. / Mode of access: World Wide Web.